For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Millenium Pharmaceuticals, Inc.

USPTO Granted Patents = 36

% Expired Patents = 25.0

EPO Patents = 1

Forward Citations = 304

Loading Chart...

Loading Chart...

112 inventors (with patents filed for the assignee):

David W White (3 out of 18 patents)

Todd B Sells (2 out of 20 patents)

Stephen G Stroud (2 out of 33 patents)

4. Robert I Tepper (2 out of 14 patents)

5. Rosana Kapeller-Libermann (2 out of 58 patents)

6. Christopher F Claiborne (2 out of 34 patents)

7. John E Monahan (2 out of 16 patents)

8. Yan Chen (2 out of 4 patents)

9. Xumei Zhao (2 out of 7 patents)

10. Janice A Culpepper (2 out of 11 patents)

11. Dean A Falb (2 out of 21 patents)

12. Louis Anthony Tartaglia (2 out of 33 patents)

13. Carlos J Gimeno (2 out of 12 patents)

14. Vicky Gavrias (2 out of 6 patents)

15. Anjali Pandey (1 out of 83 patents)

Core Competencies:

Aurora Kinase Inhibitors

PDK1 Inhibitors

Cancer Treatment

TGF-β Inhibition

Proteasome Inhibitors

Body Weight Disorders

Boronate Ester Compounds

Essential Bacterial Genes

Antibacterial Agents

Ob Receptor Antibodies

Polymorphs of Factor Xa Inhibitor

Thioredoxin Family Molecules

36 patents: Sort by Forward Citations

1. 10836766 - Aurora kinase inhibitors for inhibiting mitotic progression (2020-11-17),

2. 10604538 - Boronate ester compounds and pharmaceutical compositions thereof (2020-03-31),

3. 10030016 - Heterocyclic compounds useful as PDK1 inhibitors (2018-07-24),

4. 9765076 - Aurora kinase inhibitors for inhibiting mitotic progression (2017-09-19),

5. 8815887 - Prophylactic or therapeutic method for Sjogren's syndrome (2014-08-26),

6. 7943640 - Compositions and methods for inhibiting TGF-β (2011-05-17),

7. 7897725 - Delta3 (tango24) protein and nucleic acid molecules and uses thereof (2011-03-01),

8. 7771953 - Methods of diagnosing and treating cancer (2010-08-10),

9. 7598375 - Method of acylating maytansinol with chiral amino acids (2009-10-06),

10. 7598276 - Pharmaceutical salts and polymorphs of a factor Xa inhibitor (2009-10-06),

11. 7527962 - Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor (2009-05-05),

12. 7452967 - Molecules of the card-related protein family and uses thereof (2008-11-18),

13. 7442830 - Proteasome inhibitors (2008-10-28),

14. 7361511 - Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer (2008-04-22),

15. 7125663 - Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer (2006-10-24),

Company Overview

Millennium Pharmaceuticals, Inc., based in Cambridge, MA, is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and other serious diseases. The organization specializes in targeted therapies and personalized medicine, leveraging advanced research in genomics and molecular biology to create effective treatment options. With a commitment to improving patient outcomes, Millennium plays a significant role in the evolving landscape of oncology and therapeutic advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

36 Patents

#78 in Cambridge, MA

#561 in Massachusetts

#9,516 in US

#18,745 in the World

Cambridge, MA, United States of America

Millenium Pharmaceuticals, Inc.

Forward Citations = 304

112 inventors:

David W White (3 out of 18 patents)

Todd B Sells (2 out of 20 patents)

Stephen G Stroud (2 out of 33 patents)

4. Robert I Tepper (2 out of 14 patents)

5. Rosana Kapeller-Libermann (2 out of 58 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Millenium Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/millenium-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…